Research programme: HN-1 peptide anticancer therapeutics - Tapestry Pharmaceuticals
Alternative Names: HN-1 peptide delivery; HN-1 Taxane A proprietary synthetic peptide/paclitaxel conjugateLatest Information Update: 19 Nov 2007
At a glance
- Originator M. D. Anderson Cancer Center; Tapestry Pharmaceuticals
- Class Taxanes
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Squamous cell cancer
Most Recent Events
- 07 May 2004 NaPro Biotherapeutics is now called Tapestry Pharmaceuticals
- 03 Apr 2003 Preclinical trials in Squamous cell cancer in USA (unspecified route)